GB Patent

GB201908511D0 — Hydroxamate compounds

Assigned to AdoRx Therapeutics Ltd · Expires 2019-07-31 · 7y expired

What this patent protects

Patent listed against Retevmo.

Drugs covered by this patent

Retevmo (SELPERCATINIB) · Eli Lilly

Patent Metadata

Patent number: GB201908511D0
Jurisdiction: GB
Classification: —
Expires: 2019-07-31
Drug substance claim: No
Drug product claim: No
Assignee: AdoRx Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.